{"title":"巴斯夫投资胶原蛋白疗法","authors":"None Craig Bettenhausen","doi":"10.1021/cen-10137-buscon12","DOIUrl":null,"url":null,"abstract":"BASF has invested an undisclosed sum in the molecular biology start-up 3Helix. The firm makes specialized peptides that bind to damaged collagen molecules. 3Helix has so far commercialized its technology for medical imaging and diagnostic applications. BASF will gain exclusive rights to commercialize 3Helix’s platform for personal care applications, where a wide range of firms are building antiaging products around supporting or supplementing collagen in skin.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"28 10","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BASF invests in collagen therapy\",\"authors\":\"None Craig Bettenhausen\",\"doi\":\"10.1021/cen-10137-buscon12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BASF has invested an undisclosed sum in the molecular biology start-up 3Helix. The firm makes specialized peptides that bind to damaged collagen molecules. 3Helix has so far commercialized its technology for medical imaging and diagnostic applications. BASF will gain exclusive rights to commercialize 3Helix’s platform for personal care applications, where a wide range of firms are building antiaging products around supporting or supplementing collagen in skin.\",\"PeriodicalId\":9517,\"journal\":{\"name\":\"C&EN Global Enterprise\",\"volume\":\"28 10\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"C&EN Global Enterprise\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1021/cen-10137-buscon12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"C&EN Global Enterprise","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/cen-10137-buscon12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
BASF has invested an undisclosed sum in the molecular biology start-up 3Helix. The firm makes specialized peptides that bind to damaged collagen molecules. 3Helix has so far commercialized its technology for medical imaging and diagnostic applications. BASF will gain exclusive rights to commercialize 3Helix’s platform for personal care applications, where a wide range of firms are building antiaging products around supporting or supplementing collagen in skin.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
